A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease

Elaheh Vahabnezhad; Shervin Rabizadeh; Marla C. Dubinsky

doi:10.1097/MIB.0000000000000003

A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease

Elaheh Vahabnezhad, Shervin Rabizadeh, Marla C. Dubinsky

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

Background: Despite increasing use of infliximab (IFX) in children with Crohn's disease (CD) and ulcerative colitis (UC), long-term durability and safety of IFX beyond 1 year is limited in pediatric inflammatory bowel disease. Methods: We performed a 10-year single-center retrospective cohort study of 188 patients initiating IFX at

Original language	English (US)
Pages (from-to)	606-613
Number of pages	8
Journal	Inflammatory Bowel Diseases
Volume	20
Issue number	4
DOIs	https://doi.org/10.1097/MIB.0000000000000003
State	Published - 2014
Externally published	Yes

Keywords

Anti-infliximab antibody
Crohn's disease
Inflammatory bowel disease
Infliximab
Pediatric
Ulcerative colitis

ASJC Scopus subject areas

Gastroenterology
Immunology and Allergy
Medicine(all)

Access to Document

10.1097/MIB.0000000000000003

Cite this

@article{3b0a3c139ffe4cdfbbce17fea60fd3dc,

title = "A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease",

abstract = "Background: Despite increasing use of infliximab (IFX) in children with Crohn's disease (CD) and ulcerative colitis (UC), long-term durability and safety of IFX beyond 1 year is limited in pediatric inflammatory bowel disease. Methods: We performed a 10-year single-center retrospective cohort study of 188 patients initiating IFX at ",

keywords = "Anti-infliximab antibody, Crohn's disease, Inflammatory bowel disease, Infliximab, Pediatric, Ulcerative colitis",

author = "Elaheh Vahabnezhad and Shervin Rabizadeh and Dubinsky, {Marla C.}",

year = "2014",

doi = "10.1097/MIB.0000000000000003",

language = "English (US)",

volume = "20",

pages = "606--613",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease

AU - Vahabnezhad, Elaheh

AU - Rabizadeh, Shervin

AU - Dubinsky, Marla C.

PY - 2014

Y1 - 2014

N2 - Background: Despite increasing use of infliximab (IFX) in children with Crohn's disease (CD) and ulcerative colitis (UC), long-term durability and safety of IFX beyond 1 year is limited in pediatric inflammatory bowel disease. Methods: We performed a 10-year single-center retrospective cohort study of 188 patients initiating IFX at

AB - Background: Despite increasing use of infliximab (IFX) in children with Crohn's disease (CD) and ulcerative colitis (UC), long-term durability and safety of IFX beyond 1 year is limited in pediatric inflammatory bowel disease. Methods: We performed a 10-year single-center retrospective cohort study of 188 patients initiating IFX at

KW - Anti-infliximab antibody

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Infliximab

KW - Pediatric

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84898735318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898735318&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000003

DO - 10.1097/MIB.0000000000000003

M3 - Article

C2 - 24552827

AN - SCOPUS:84898735318

SN - 1078-0998

VL - 20

SP - 606

EP - 613

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

IS - 4

ER -

A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this